MENLO PARK, Calif., June 21 /PRNewswire/ -- Solazyme, a leading algal biotechnology company, today announced that it has been awarded a Phase I STTR to pursue genetic engineering of Dunaliella, a green eukaryotic microalgae.
Dunaliella is known for its ability to accumulate significant quantities of lipids suitable for biodiesel and for its ability to accumulate large quantities of beta-carotene, which is currently used for both human/animal nutrition and as an additive to reduce emissions from diesel fuels. It also produces a number of other high value compounds. The laboratory of Dr. Jurgen Polle at Brooklyn College of the City University of New York, an acknowledged leader in Dunaliella physiology and genetics is the STTR partner in this program.
“The award of this grant is exciting and provides external validation of the preliminary data and of the overall project goals,” said Dr. Anthony G. Day, VP of Research and Development at Solazyme.
More information on Solazyme can be found online at www.solazyme.com and more information of Brooklyn College can be found at www.brooklyn.cuny.edu.
About Solazyme:
Founded in 2003 in Menlo Park, California, Solazyme is devoted to harnessing the energy-harvesting machinery of various species of algae to produce valuable products. The Company utilizes proprietary genetic engineering methods to develop and optimize commercially relevant biochemical pathways for production of Nutraceutical/Cosmeceutical and Pharmaceutical products. For more information, please visit our website: www.solazyme.com or contact Jonathan Wolfson at 650-780-4777.
Solazyme
CONTACT: Jonathan Wolfson of Solazyme, +1-650-780-4777
Web site: http://www.solazyme.com//
